IMPRINTER: an Open Label, Multicenter, Dose Escalation/expansion, Phase 1 Study of Imu-201 (Pd1-Vaxx), a B-cell Immunotherapy As Monotherapy or in Combination with Atezolizumab, in Adults with Non-Small Cell Lung Cancer (IMU.201.101).
Journal of clinical oncology（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要